|
Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Sanofi |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Ipsen; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda |
Speakers' Bureau - Amgen; Astellas Pharma; Janssen Oncology; Sanofi |
Travel, Accommodations, Expenses - Amgen |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Janssen; Pierre Fabre; Sanofi |
Travel, Accommodations, Expenses - Bayer; Sanofi |